Literature DB >> 4303789

Some determinants of the effects of VAL-5-angiotensin II amide on glomerular filtration rate and sodium excretion in dogs.

J C McGiff, J R Lynch, J A Leinicke, J C Strand, A Aboosi.   

Abstract

In 12 dogs anesthetized with chloralose, angiotensin (angiotensin II amide) given intravenously increased the glomerular filtration rate (GFR) of an ischemic kidney while simultaneously having little effect on the GFR of the contralateral kidney. In the ischemic kidney, in 14 of 30 observations, increments of GFR greater than 100% of mean control GFR (9 ml/min) occurred in response to angiotensin. The magnitude of the increase in GFR produced by angiotensin was independent of dose (range 0.005-0.050 mug/kg per min), the degree of accompanying pressor response, and alterations in renal blood flow (RBF) (electromagnetic flow-meter). In the ischemic kidney, increments of GFR could be produced by sub-pressor doses of angiotensin. Dissociations between increments of GFR and sodium excretion occurred. Equivalent increments of GFR in the ischemic kidney in dogs receiving either 5% glucose in water or 10% mannitol in 0.3% saline were associated with natriuresis only in the latter group: a) as an initial response of the contralateral kidney to renal arterial constriction (RAC) in spite of a concomitant reduction in RBF and an unchanged GFR; b) in the ischemic kidney on giving angiotensin. The natriuresis produced by angiotensin was independent of the magnitude of elevations in blood pressure, altered filtration fraction, and was associated with a further reduction in RBF. After release of RAC in the dogs receiving mannitol, an antinatriuresis was again observed in response to angiotensin. The presence of unilateral renal ischemia allowed the demonstration of a differential action of angiotensin on the GFR of an ischemic and nonischemic kidney. The natriuresis in response to angiotensin requires, in addition to mannitol, the participation of undefined factors invoked by unilateral renal ischemia.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4303789      PMCID: PMC322200          DOI: 10.1172/JCI105963

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  THE INNERVATION OF THE JUXTAGLOMERULAR APPARATUS. AN ELECTRON MICROSCOPIC STUDY OF THE INNERVATION OF THE GLOMERULAR ARTERIOLES.

Authors:  L BARAJAS
Journal:  Lab Invest       Date:  1964-08       Impact factor: 5.662

2.  RENAL AND PRESSOR ACTION OF ANGIOTENSIN IN THE NORMAL DOG.

Authors:  J K HEALY; C BARCENA; J M O'CONNELL; G E SCHREINER
Journal:  Am J Physiol       Date:  1965-06

3.  INHIBITION OF RENAL TUBULAR SODIUM REABSORPTION BY HYPERNATREMIA.

Authors:  D E KAMM; N G LEVINSKY
Journal:  J Clin Invest       Date:  1965-07       Impact factor: 14.808

4.  [A simple colorimetric method of inulin determination in renal clearance studies on metabolically normal subjects and diabetics].

Authors:  J FUHR; J KACZMARCZYK; C D KRUTTGEN
Journal:  Klin Wochenschr       Date:  1955-08-01

5.  Intrarenal function of angiotensin.

Authors:  P P Leyssac
Journal:  Fed Proc       Date:  1967 Jan-Feb

Review 6.  Control of renin release.

Authors:  A J Vander
Journal:  Physiol Rev       Date:  1967-07       Impact factor: 37.312

7.  Effect of hypertonic mannitol solution on circulation and renal function in acute blood loss.

Authors:  G Szabó; S Magyar
Journal:  Acta Med Acad Sci Hung       Date:  1967

8.  Role of acetylcholine in the renal vasoconstrictor response to sympathetic nerve stimulation in the dog.

Authors:  J C McGiff; R B Burns; M R Blumenthal
Journal:  Circ Res       Date:  1967-06       Impact factor: 17.367

9.  The Effects of Angiotensin II on Renal Water and Electrolyte Excretion in Normal and Caval Dogs.

Authors:  J G Porush; G J Kaloyanides; R J Cacciaguida; S M Rosen
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

10.  Conversion of angiotensin I to angiotensin II.

Authors:  K K Ng; J R Vane
Journal:  Nature       Date:  1967-11-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.